Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
RZLT

RZLT - Rezolute, Inc. Stock Price, Fair Value and News

4.24USD+0.29 (+7.34%)Market Closed

Market Summary

RZLT
USD4.24+0.29
Market Closed
7.34%

RZLT Alerts

  • 2 major insider buys recently.

RZLT Stock Price

View Fullscreen

RZLT RSI Chart

RZLT Valuation

Market Cap

158.5M

Price/Earnings (Trailing)

-2.72

Price/Sales (Trailing)

29.89

Price/Free Cashflow

-3.16

RZLT Price/Sales (Trailing)

RZLT Profitability

Return on Equity

-82.17%

Return on Assets

-66.36%

Free Cashflow Yield

-31.67%

RZLT Fundamentals

RZLT Revenue

Revenue (TTM)

5.3M

Rev. Growth (Yr)

-24.39%

Rev. Growth (Qtr)

-13.89%

RZLT Earnings

Earnings (TTM)

-58.2M

Earnings Growth (Yr)

-8.79%

Earnings Growth (Qtr)

-22.58%

Breaking Down RZLT Revenue

Last 7 days

-0.2%

Last 30 days

40.2%

Last 90 days

97%

Trailing 12 Months

83.3%

How does RZLT drawdown profile look like?

RZLT Financial Health

Current Ratio

11.82

Debt/Equity

0.2

Debt/Cashflow

-3.52

RZLT Investor Care

Shares Dilution (1Y)

8.98%

Diluted EPS (TTM)

-1.15

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20245.3M000
20232.8M4.2M5.2M5.7M
202275.0K81.0K480.0K1.3M
2021725.0K63.0K069.0K
20201.7M1.2M1.2M1.4M
2019745.3K1.3M1.6M1.7M
20181.2M762.0K660.3K532.5K
2017661.1K1.1M1.2M1.3M
2016495.6K442.0K466.1K489.8K
2015682.7K539.5K378.0K461.1K
2014502.2K684.1K886.4K838.7K
2013565.4K634.1K597.8K540.1K
2012261.7K0362.9K464.2K
2011000160.5K

Tracking the Latest Insider Buys and Sells of Rezolute, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 14, 2024
roberts brian kenneth
bought
1,190
3.9699
300
chief medical officer
Jun 14, 2024
roberts brian kenneth
bought
11,724
3.9082
3,000
chief medical officer
Jun 14, 2024
roberts brian kenneth
bought
16,827
3.9134
4,300
chief medical officer
Jun 14, 2024
evans daron
bought
161,568
4.0392
40,000
cfo
May 29, 2024
evans daron
bought
1,578
3.5
451
cfo
May 24, 2024
evans daron
bought
9,502
3.23
2,942
cfo
May 23, 2024
roberts brian kenneth
bought
20,137
2.68504
7,500
chief medical officer
May 23, 2024
evans daron
bought
165
2.85
58.00
cfo
Mar 28, 2024
roberts brian kenneth
bought
1,275
2.55
500
chief medical officer
Mar 15, 2024
evans daron
bought
33,830
1.6915
20,000
cfo

1–10 of 50

Which funds bought or sold RZLT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 20, 2024
Virtu Financial LLC
new
-
37,000
37,000
-%
May 15, 2024
Cubist Systematic Strategies, LLC
new
-
29,682
29,682
-%
May 15, 2024
STATE STREET CORP
unchanged
-
92,784
151,909
-%
May 15, 2024
MORGAN STANLEY
unchanged
-
3,226
5,281
-%
May 15, 2024
FIRST MANHATTAN CO. LLC.
sold off
-100
-2,660,870
-
-%
May 15, 2024
BANK OF AMERICA CORP /DE/
sold off
-100
-40.00
-
-%
May 15, 2024
SILVERARC CAPITAL MANAGEMENT, LLC
reduced
-3.25
231,655
387,562
0.11%
May 15, 2024
CITADEL ADVISORS LLC
added
14.97
672,029
1,015,980
-%
May 15, 2024
Blackstone Inc.
unchanged
-
2,394,940
3,921,090
0.02%
May 15, 2024
BOOTHBAY FUND MANAGEMENT, LLC
unchanged
-
18,690
30,600
-%

1–10 of 41

Are Funds Buying or Selling RZLT?

Are funds buying RZLT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own RZLT
No. of Funds

Unveiling Rezolute, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 11, 2024
nantahala capital management, llc
9.9%
4,118,164
SC 13G
Feb 13, 2024
vivo opportunity fund holdings, l.p.
8.2%
3,242,842
SC 13G/A
Feb 13, 2024
stonepine capital management, llc
7.0%
2,768,656
SC 13G/A
Feb 12, 2024
first manhattan co. llc.
6.77%
2,680,978
SC 13G/A
Jan 18, 2024
federated hermes, inc.
19.99%
8,250,274
SC 13G/A
Oct 13, 2023
vivo opportunity fund holdings, l.p.
8.8%
3,242,842
SC 13G
May 03, 2023
genexine inc.
4.96%
1,826,019
SC 13D/A
Feb 14, 2023
caxton corp
4.99%
1,860,518
SC 13G/A
Feb 14, 2023
first manhattan co
8.48%
3,123,078
SC 13G
Feb 13, 2023
stonepine capital management, llc
8.2%
3,021,504
SC 13G/A

Recent SEC filings of Rezolute, Inc.

View All Filings
Date Filed Form Type Document
Jun 14, 2024
4
Insider Trading
Jun 14, 2024
4
Insider Trading
Jun 14, 2024
424B5
Prospectus Filed
Jun 14, 2024
8-K
Current Report
Jun 13, 2024
424B5
Prospectus Filed
May 31, 2024
4
Insider Trading
May 28, 2024
4
Insider Trading
May 28, 2024
4
Insider Trading
May 24, 2024
8-K
Current Report
May 17, 2024
8-K
Current Report

Peers (Alternatives to Rezolute, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
51.1B
6.8B
-18.41% 10.61%
-8.56
7.46
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
21.0B
2.0B
9.73% -16.82%
-63.12
10.46
75.20% 68.82%
15.9B
2.5B
9.61% -12.35%
77.43
6.44
13.74% 186.89%
14.2B
3.8B
8.63% 2.12%
19.04
3.77
8.58% 129.81%
MID-CAP
5.1B
107.9M
-6.63% 69.33%
-9.37
48.09
54.84% -28.31%
4.6B
524.1M
-12.71% -56.08%
-11.07
8.82
394.93% 39.61%
3.6B
251.0M
-0.36% -15.32%
-12.24
14.45
73.58% -86.73%
3.2B
240.7M
1.47% -28.24%
-6.69
12.77
-1.03% -213.92%
2.5B
813.8M
-3.10% -36.23%
-1.5K
3.11
56.43% 98.83%
2.0B
996.6M
-10.70% 95.81%
-4.94
1.98
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-3.41% 18.74%
28.28
4.48
60.38% -34.49%
453.7M
881.7K
-5.58% 440.76%
-13.44
481.06
-77.61% 33.36%
209.4M
4.2M
-28.18% 49.63%
-1.68
50.33
-66.30% 48.24%
18.2M
2.1M
-6.22% 224.62%
-0.79
7.61
-13.45% 69.54%

Rezolute, Inc. News

Latest updates
StockTitan11 hours ago
Yahoo Movies Canada16 Jun 202410:45 am

Rezolute, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-13.9%1,1221,3031,4041,4751,48484940067.00-13.001.0024148137021731927336071139486.00
Operating Expenses6.7%16,21315,19415,91414,23817,14214,39210,21811,30010,75412,1496,6365,4837,1523,6233,5525,0706,7205,1793,18417,0373,161
  S&GA Expenses20.8%3,8123,1553,7003,3052,9113,4472,5142,7262,0682,6972,2471,7252,6561,2791,1071,3371,6821,9451,5111,9261,773
  R&D Expenses3.0%12,40112,03912,21410,93314,23110,9457,7048,5748,6869,4524,3893,7584,4962,3442,4453,7335,0383,2341,71815,1221,309
Interest Expenses--------476331340--------3,50743.001,288
Income Taxes----------------------
Net Income-22.6%-17,050-13,909-14,524-12,741-15,672-13,556-9,831-9,423-11,208-12,593-6,490-3,695-7,097-3,620-3,547-5,040-6,666-5,080-3,147-19,772-4,162
Net Income Margin-9.4%-10.98*-10.03*-10.84*-12.31*-17.32*-33.45*-89.70*-506.91*-508.36*-443.68*-331.78*----------
Free Cashflow-17.1%-15,246-13,015-10,585-11,400-18,018-7,576-7,659-12,110-13,968-7,197-5,230----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-14.1%88.0010211312413415015615270.0083.0039.0043.0033.0039.007.0011.0015.0021.0027.0012.0015.00
  Current Assets-14.4%82.0096.0010310510614815615264.0078.0038.0042.0032.0038.007.0011.0014.0020.0026.0012.0015.00
    Cash Equivalents-52.6%6.0013.008.0016.0034.0014715415063.0082.0037.0041.0032.0038.006.0010.0014.0018.0022.0038.0015.00
  Net PPE-7.6%0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
Liabilities62.2%17.0010.009.008.007.009.003.003.0018.0021.0017.0017.004.003.003.004.004.006.006.0011.0011.00
  Current Liabilities-13.0%7.008.007.005.004.006.002.002.003.006.003.002.004.003.003.003.004.006.006.008.007.00
  Long Term Debt---------14.0014.0014.0014.00---------
Shareholder's Equity-22.7%71.0092.0010411612714115314952.0062.0022.0026.0029.0036.004.007.0010.0015.0021.002.005.00
  Retained Earnings-5.9%-306-289-275-260-248-232-219-209-199-188-175-168-161-157-150-147-143-138-131-126-123
  Additional Paid-In Capital-1.0%37738137937737637437235925225119819419119415515515415315212997.00
Shares Outstanding1.3%40.0040.0037.0037.0051.0051.0051.0034.0017.0016.009.008.00---------
Float------64.00---61.00---76.00---13.00---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-17.1%-15,246-13,015-10,585-11,369-18,049-7,493-7,589-12,110-13,968-7,197-6,341-5,230-5,397-6,263-3,551-4,078-5,679-5,482-8,929-3,765-8,456
  Share Based Compensation3.6%1,9031,8371,8491,8031,8551,7311,8799848501,0098421,6605301,1416345836756651,394247695
Cashflow From Investing-51.2%8,67017,7602,606-6,357-94,954-83.00-70.00-------------6.0042.00
Cashflow From Financing-Infinity%-3.00-----11,57194,104-19.0052,3082,58614,288-21437,459----21.0022,571-23,500
  Buy Backs-5,700--------------------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

RZLT Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:    
Research and development$ 12,401$ 14,231$ 36,654$ 32,880
General and administrative3,8122,91110,6678,872
Total operating expenses16,21317,14247,32141,752
Operating loss(16,213)(17,142)(47,321)(41,752)
Non-operating income (expense):    
Interest and other income, net1,1221,4843,8292,733
Loss from change in fair value of derivative liabilities(1,959)(14)(1,991)(40)
Total non-operating income (expense), net(837)1,4701,8382,693
Net loss(17,050)(15,672)(45,483)(39,059)
Other comprehensive income (loss):    
Net unrealized gain (loss) on available-for-sale marketable debt securities(30)(132)273(132)
Comprehensive loss$ (17,080)$ (15,804)$ (45,210)$ (39,191)
Net loss per common share - basic (in dollars per share)$ (0.34)$ (0.30)$ (0.89)$ (0.76)
Net loss per common share - diluted (in dollars per share)$ (0.34)$ (0.30)$ (0.89)$ (0.76)
Weighted average number of common shares outstanding - basic (in shares)50,81151,40951,21251,113
Weighted average number of common shares outstanding - diluted (in shares)50,81151,40951,21251,113

RZLT Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Jun. 30, 2023
Current assets:  
Cash and cash equivalents$ 5,930$ 16,036
Investments in marketable debt securities74,09285,860
Prepaid expenses and other2,1883,014
Total current assets82,210104,910
Long-term assets:  
Investments in marketable debt securities1,57316,470
Right-of-use assets2,0062,054
Property and equipment, net110139
Deposits and other1,838148
Total assets87,737123,721
Current liabilities:  
Accounts payable3,4993,269
Accrued liabilities:  
Accrued clinical and other2,027507
Compensation and benefits879883
Current portion of operating lease liabilities552541
Total current liabilities6,9575,200
Long term liabilities:  
Operating lease liabilities, net of current portion1,8191,937
Warrant derivative liability7,647 
Embedded derivative liability453412
Total liabilities16,8767,549
Commitments and contingencies (Notes 5, 9 and 10)
Shareholders' equity:  
Preferred stock, $0.001 par value; 400 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 100,000 shares authorized; issued and outstanding 40,132 and 36,827 shares as of March 31, 2024 and June 30, 2023, respectively4037
Additional paid-in capital377,367377,471
Accumulated other comprehensive loss(78)(351)
Accumulated deficit(306,468)(260,985)
Total shareholders' equity70,861116,172
Total liabilities and shareholders' equity$ 87,737$ 123,721
RZLT
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
 CEO
 WEBSITErezolutebio.com
 INDUSTRYBiotechnology
 EMPLOYEES47

Rezolute, Inc. Frequently Asked Questions


What is the ticker symbol for Rezolute, Inc.? What does RZLT stand for in stocks?

RZLT is the stock ticker symbol of Rezolute, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Rezolute, Inc. (RZLT)?

As of Fri Jun 21 2024, market cap of Rezolute, Inc. is 158.53 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RZLT stock?

You can check RZLT's fair value in chart for subscribers.

What is the fair value of RZLT stock?

You can check RZLT's fair value in chart for subscribers. The fair value of Rezolute, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Rezolute, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RZLT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Rezolute, Inc. a good stock to buy?

The fair value guage provides a quick view whether RZLT is over valued or under valued. Whether Rezolute, Inc. is cheap or expensive depends on the assumptions which impact Rezolute, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RZLT.

What is Rezolute, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 21 2024, RZLT's PE ratio (Price to Earnings) is -2.72 and Price to Sales (PS) ratio is 29.89. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RZLT PE ratio will change depending on the future growth rate expectations of investors.